Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro

Transplant International

Volumn 28, Issue 10, 2015, Pages 1152-1161

  Kloster Jensen, Kristine ^a,b   Vethe, Nils Tore ^a   Bremer, Sara ^a   Abadpour, Shadab ^a,b   Korsgren, Olle ^c   Foss, Aksel ^a,b,d   Bergan, Stein ^a,e   Scholz, Hanne ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

diabetes; human islets; immunosuppressive drugs; intracellular drug concentration; sirolimus; tacrolimus

Indexed keywords

CYTOCHROME P450 3A4; MAMMALIAN TARGET OF RAPAMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; RAPAMYCIN; S6 KINASE; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TACROLIMUS; ABCB1 PROTEIN, HUMAN; CYCLOSPORIN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INTERACTION; ELECTROSPRAY MASS SPECTROMETRY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MASS SPECTROMETER; OXYGEN CONSUMPTION; PANCREAS ISLET; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; AGED; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; OSMOLARITY; PHOSPHORYLATION; PROTEIN PROCESSING; TRANSPORT AT THE CELLULAR LEVEL; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL TRANSPORT; CELLS, CULTURED; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; GLUCOSE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; OSMOLAR CONCENTRATION; OXYGEN CONSUMPTION; P-GLYCOPROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; TACROLIMUS; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84940786894     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12617     Document Type: Article

References (47)

1. Barton FB, Rickels MR, Alejandro R, et al,. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012; 35: 1436.
2. Nanji SA, Shapiro AM,. Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs 2004; 18: 315.
3. Vafadari R, Kraaijeveld R, Weimar W, Baan CC,. Tacrolimus inhibits NF-kappaB activation in peripheral human T cells. PLoS ONE 2013; 8: e60784.
4. Bugliani M, Masini M, Liechti R, et al,. The direct effects of tacrolimus and cyclosporin A on isolated human islets: a functional, survival and gene expression study. Islets 2009; 1: 106.
5. Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP,. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996; 98: 2786.
6. Bechstein WO, Paczek L, Wramner L, Squifflet JP, Zygmunt AJ, and European Rapamune Tacrolimus Study Group. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. Transplant Proc, 2013; 45: 2133.
7. Posselt AM, Szot GL, Frassetto LA, et al,. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation 2010; 90: 1595.
8. Auer VJ, Janas E, Ninichuk V, et al,. Extracellular factors and immunosuppressive drugs influencing insulin secretion of murine islets. Clin Exp Immunol 2012; 170: 238.
9. Bussiere CT, Lakey JR, Shapiro AM, Korbutt GS,. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 2006; 49: 2341.
10. Marcelli-Tourvieille S, Hubert T, Moerman E, et al,. In vivo and in vitro effect of sirolimus on insulin secretion. Transplantation 2007; 83: 532.
11. Niclauss N, Bosco D, Morel P, Giovannoni L, Berney T, Parnaud G,. Rapamycin impairs proliferation of transplanted islet beta cells. Transplantation 2011; 91: 714.
12. Piao SG, Bae SK, Lim SW, et al,. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction. Transplantation 2012; 93: 383.
13. Shapiro AM, Gallant HL, Hao EG, et al,. The portal immunosuppressive storm: relevance to islet transplantation? Ther Drug Monit 2005; 27: 35.
14. Dollery CT,. Intracellular drug concentrations. Clin Pharmacol Ther 2013; 93: 263.
15. Christians U, Strom T, Zhang YL, et al,. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 2006; 28: 39.
16. Iwasaki K,. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007; 22: 328.
17. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B,. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004; 1: 27.
18. Bani D, Brandi ML, Axiotis CA, Bani-Sacchi T,. Detection of P-glycoprotein on endothelial and endocrine cells of the human pancreatic islets by C 494 monoclonal antibody. Histochemistry 1992; 98: 207.
19. Standop J, Schneider M, Ulrich A, Buchler MW, Pour PM,. Differences in immunohistochemical expression of xenobiotic-metabolizing enzymes between normal pancreas, chronic pancreatitis and pancreatic cancer. Toxicol Pathol 2003; 31: 506.
20. Ulrich AB, Standop J, Schmied BM, Schneider MB, Lawson TA, Pour PM,. Species differences in the distribution of drug-metabolizing enzymes in the pancreas. Toxicol Pathol 2002; 30: 247.
21. Niemi M,. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8: 787.
22. Meyer Zu Schwabedissen HE, Boettcher K, Steiner T, et al,., OATP1B3 is expressed in pancreatic beta-islet cells and enhances the insulinotropic effect of the sulfonylurea derivative glibenclamide. Diabetes, 2014; 63: 775.
23. Capron A, Lerut J, Latinne D, Rahier J, Haufroid V, Wallemacq P,. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. Transpl Int 2012; 25: 41.
24. Kwon G, Marshall CA, Pappan KL, Remedi MS, McDaniel ML,. Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. Diabetes 2004; 53 (Suppl. 3): S225.
25. Goto M, Eich TM, Felldin M, et al,. Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture. Transplantation 2004; 78: 1367.
26. Johnson JD, Ao Z, Ao P, et al,. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplant 2009; 18: 833.
27. Sweet IR, Gilbert M, Scott S, et al,. Glucose-stimulated increment in oxygen consumption rate as a standardized test of human islet quality. Am J Transplant 2008; 8: 183.
28. Ulvestad M, Skottheim IB, Jakobsen GS, et al,. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther 2013; 93: 275.
29. Will Y, Hynes J, Ogurtsov VI, Papkovsky DB,. Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes. Nat Protoc 2006; 1: 2563.
30. Dong M, Parsaik AK, Eberhardt NL, Basu A, Cosio FG, Kudva YC,. Cellular and physiological mechanisms of new-onset diabetes mellitus after solid organ transplantation. Diabet Med 2012; 29: e1.
31. Staatz CE, Tett SE,. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623.
32. Venkataramanan R, Swaminathan A, Prasad T, et al,. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404.
33. Mahalati K, Kahan BD,. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001; 40: 573.
34. Undre NA,. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 2003; 18 (Suppl. 1): i12.
35. Bierer BE, Mattila PS, Standaert RF, et al,. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci USA 1990; 87: 9231.
36. Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fischer PA, Sigal NH,. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418.
37. van Rossum HH, Romijn FP, Smit NP, de Fijter JW, van Pelt J,. Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12. Biochem Pharmacol 2009; 77: 1206.
38. Zahr E, Molano RD, Pileggi A, et al,. Rapamycin impairs in vivo proliferation of islet beta-cells. Transplantation 2007; 84: 1576.
39. Chung J, Kuo CJ, Crabtree GR, Blenis J,. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992; 69: 1227.
40. Terada N, Lucas JJ, Szepesi A, Franklin RA, Takase K, Gelfand EW,. Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. Biochem Biophys Res Commun 1992; 186: 1315.
41. International Transporter Consortium, Giacomini KM, Huang SM, et al,. Membrane transporters in drug development. Nat Rev Drug Discov, 2010; 9: 215.
42. Ulrich AB, Standop J, Schmied BM, Schneider MB, Lawson TA, Pour PM,. Expression of drug-metabolizing enzymes in the pancreas of hamster, mouse, and rat, responding differently to the pancreatic carcinogenicity of BOP. Pancreatology 2002; 2: 519.
43. Khan S, Khan S, Baboota S, Ali J,. Immunosuppressive drug therapy-biopharmaceutical challenges and remedies. Expert Opin Drug Deliv 2015; doi: 10.1517/17425247.2015.1005072 [Epub ahead of print].
44. Provenzani A, Santeusanio A, Mathis E, et al,. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol 2013; 19: 9156.
45. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y,. Long-term pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients. Ther Drug Monit 2003; 25: 447.
46. Ciancio G, Burke GW, Gaynor JJ, et al,. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77: 252.
47. Gillard P, Ling Z, Mathieu C, et al,. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. Transplantation 2008; 85: 256.